These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 29296532)

  • 21. Chemokine receptors expression and migration potential of tumor-infiltrating and peripheral-expanded Vgamma9Vdelta2 T cells from renal cell carcinoma patients.
    Viey E; Lucas C; Romagne F; Escudier B; Chouaib S; Caignard A
    J Immunother; 2008 Apr; 31(3):313-23. PubMed ID: 18317356
    [TBL] [Abstract][Full Text] [Related]  

  • 22. BTN3A molecules considerably improve Vγ9Vδ2T cells-based immunotherapy in acute myeloid leukemia.
    Benyamine A; Le Roy A; Mamessier E; Gertner-Dardenne J; Castanier C; Orlanducci F; Pouyet L; Goubard A; Collette Y; Vey N; Scotet E; Castellano R; Olive D
    Oncoimmunology; 2016; 5(10):e1146843. PubMed ID: 27853633
    [TBL] [Abstract][Full Text] [Related]  

  • 23. V gamma 9V delta 2 T cells impair intracellular multiplication of Brucella suis in autologous monocytes through soluble factor release and contact-dependent cytotoxic effect.
    Ottones F; Dornand J; Naroeni A; Liautard JP; Favero J
    J Immunol; 2000 Dec; 165(12):7133-9. PubMed ID: 11120844
    [TBL] [Abstract][Full Text] [Related]  

  • 24. An organotypic human melanoma-in-skin model as an
    Michielon E; King LA; Waaijman T; Veth M; Spiekstra SW; van der Vliet HJ; Gibbs S; de Gruijl TD
    Immunooncol Technol; 2024 Dec; 24():100724. PubMed ID: 39220726
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Targeting BTN2A1 enhances Vγ9Vδ2 T-cell effector functions and triggers tumor cell pyroptosis.
    Le Floch AC; Imbert C; Boucherit N; Gorvel L; Fattori S; Orlanducci F; Le Roy A; Archetti L; Crescence L; Panicot-Dubois L; Dubois C; Vey N; Briantais A; Anastasio A; Cano C; Guittard G; Frechin M; Olive D
    Cancer Immunol Res; 2024 Sep; ():. PubMed ID: 39302336
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Low-Density Lipoprotein Uptake Inhibits the Activation and Antitumor Functions of Human Vγ9Vδ2 T Cells.
    Rodrigues NV; Correia DV; Mensurado S; Nóbrega-Pereira S; deBarros A; Kyle-Cezar F; Tutt A; Hayday AC; Norell H; Silva-Santos B; Dias S
    Cancer Immunol Res; 2018 Apr; 6(4):448-457. PubMed ID: 29358174
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Role of NKG2D and its ligands in the anti-infectious activity of Vγ9Vδ2 T cells against intracellular bacteria.
    Bessoles S; Ni M; Garcia-Jimenez S; Sanchez F; Lafont V
    Eur J Immunol; 2011 Jun; 41(6):1619-28. PubMed ID: 21469127
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Vgamma9Vdelta2 T cells use a combination of mechanisms to limit the spread of the pathogenic bacteria Brucella.
    Oliaro J; Dudal S; Liautard J; Andrault JB; Liautard JP; Lafont V
    J Leukoc Biol; 2005 May; 77(5):652-60. PubMed ID: 15668339
    [TBL] [Abstract][Full Text] [Related]  

  • 29. γδ T Cell Immunotherapy-A Review.
    Kobayashi H; Tanaka Y
    Pharmaceuticals (Basel); 2015 Feb; 8(1):40-61. PubMed ID: 25686210
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tim-3 suppresses the killing effect of Vγ9Vδ2 T cells on colon cancer cells by reducing perforin and granzyme B expression.
    Li X; Lu H; Gu Y; Zhang X; Zhang G; Shi T; Chen W
    Exp Cell Res; 2020 Jan; 386(1):111719. PubMed ID: 31726050
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In vivo immunomanipulation of V gamma 9V delta 2 T cells with a synthetic phosphoantigen in a preclinical nonhuman primate model.
    Sicard H; Ingoure S; Luciani B; Serraz C; Fournié JJ; Bonneville M; Tiollier J; Romagné F
    J Immunol; 2005 Oct; 175(8):5471-80. PubMed ID: 16210655
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Vγ9Vδ2 T cells and zoledronate mediate antitumor activity in an orthotopic mouse model of human chondrosarcoma.
    Sun L; Li Y; Jiang Z; Zhang J; Li H; Li B; Ye Z
    Tumour Biol; 2016 Jun; 37(6):7333-44. PubMed ID: 26676633
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CD94/NKG2 inhibitory receptor complex modulates both anti-viral and anti-tumoral responses of polyclonal phosphoantigen-reactive V gamma 9V delta 2 T lymphocytes.
    Poccia F; Cipriani B; Vendetti S; Colizzi V; Poquet Y; Battistini L; López-Botet M; Fournié JJ; Gougeon ML
    J Immunol; 1997 Dec; 159(12):6009-17. PubMed ID: 9550399
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Improving the Efficiency of Vγ9Vδ2 T-Cell Immunotherapy in Cancer.
    Hoeres T; Smetak M; Pretscher D; Wilhelm M
    Front Immunol; 2018; 9():800. PubMed ID: 29725332
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Large-scale expansion of Vγ9Vδ2 T cells with engineered K562 feeder cells in G-Rex vessels and their use as chimeric antigen receptor-modified effector cells.
    Xiao L; Chen C; Li Z; Zhu S; Tay JC; Zhang X; Zha S; Zeng J; Tan WK; Liu X; Chng WJ; Wang S
    Cytotherapy; 2018 Mar; 20(3):420-435. PubMed ID: 29402645
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cytokine-mediated activation of human ex vivo-expanded Vγ9Vδ2 T cells.
    Domae E; Hirai Y; Ikeo T; Goda S; Shimizu Y
    Oncotarget; 2017 Jul; 8(28):45928-45942. PubMed ID: 28521284
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phosphostim-activated gamma delta T cells kill autologous metastatic renal cell carcinoma.
    Viey E; Fromont G; Escudier B; Morel Y; Da Rocha S; Chouaib S; Caignard A
    J Immunol; 2005 Feb; 174(3):1338-47. PubMed ID: 15661891
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Partial and ineffective activation of V gamma 9V delta 2 T cells by Mycobacterium tuberculosis-infected dendritic cells.
    Meraviglia S; Caccamo N; Salerno A; Sireci G; Dieli F
    J Immunol; 2010 Aug; 185(3):1770-6. PubMed ID: 20592281
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dual Face of Vγ9Vδ2-T Cells in Tumor Immunology: Anti- versus Pro-Tumoral Activities.
    Xiang Z; Tu W
    Front Immunol; 2017; 8():1041. PubMed ID: 28894450
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In vivo phosphoantigen levels in bisphosphonate-treated human breast tumors trigger Vγ9Vδ2 T-cell antitumor cytotoxicity through ICAM-1 engagement.
    Benzaïd I; Mönkkönen H; Bonnelye E; Mönkkönen J; Clézardin P
    Clin Cancer Res; 2012 Nov; 18(22):6249-59. PubMed ID: 23032740
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.